ReviewExpert opinion on biological therapy2008
Antibody-cytokine fusion proteins: applications in cancer therapy.
Review in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Single-Chain Variable Fragment Fusion Proteins for Targeted Delivery and Therapy.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Multiscale conformational sampling of multidomain fusion proteins by a physics informed diffusion model.bioRxiv : the preprint server for biology · 2026Article
- Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy.Exploration of targeted anti-tumor therapy · 2024Review
- Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of itsCurrent pharmaceutical design · 2024Article
- 89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.Molecular cancer therapeutics · 2022Article
- Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle.Scientific reports · 2020Article
- Immunostimulatory biomaterials to boost tumor immunogenicity.Biomaterials science · 2020Review
- Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein.Cytokine · 2019Article
- Human Mast Cells From Adipose Tissue Target and Induce Apoptosis of Breast Cancer Cells.Frontiers in immunology · 2019Article
- Combination of PET and CXCR4-Targeted Peptide Molecule Agents for Noninvasive Tumor Monitoring.Journal of Cancer · 2019Article
- Review
- Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy.Frontiers in immunology · 2017Review
- Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Synthetic biology in mammalian cells: next generation research tools and therapeutics.Nature reviews. Molecular cell biology · 2014Review
- Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.Journal of controlled release : official journal of the Controlled Release Society · 2013Article
- Novel antibody-based proteins for cancer immunotherapy.Cancers · 2011Article
- Cancer vaccine development: designing tumor cells for greater immunogenicity.Frontiers in bioscience (Landmark edition) · 2010Article
- Spaceflight effects on T lymphocyte distribution, function and gene expression.Journal of applied physiology (Bethesda, Md. : 1985) · 2009Article
- Article
- Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAntibody-cytokine fusion proteins consist of cytokines fused to an antibody to improve antibody-targeted cancer immunotherapy. These molecules have the capacity to enhance the tumoricidal activity of the antibodies and/or activate a secondary antitumor immune response.
objectiveTo review the strategies used to develop antibody-cytokine fusion proteins and their in vitro and in vivo properties, including preclinical and clinical studies focusing on IL-2, IL-12 and GM-CSF.
methodsArticles were found by searching databases such as PubMed and Clinical Trials of the US National Institutes of Health. RESULTS/
conclusionMultiple antibody-cytokine fusion proteins have demonstrated significant antitumor activity as direct therapeutics or as adjuvants of cancer vaccines in preclinical studies, paving the way for their clinical evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.